Technology markets remain focused on the global artificial intelligence investment boom, with major firms continuing to spend heavily on chips, data centres and enterprise tools. Investors are… Read More...
The US Food and Drug Administration on March 27 approved the first gene therapy for severe Leukocyte Adhesion Deficiency Type 1 (LAD-1), a rare immune disorder, Medscape reported. The approval marks a… Read More...
